Autoimmune Disease Diagnostics Market size was valued at USD 4.2 billion in 2021 and is anticipated to grow at USD 6.4 billion till 2028 recording a CAGR of 8.9% during the forecast period 2022-2028. The immune system protects the body from infections and diseases. In autoimmune disorders low or overactivity of immune system may appear. There is no exact cause of autoimmune diseases are identified. In response to unknown trigger, immune system produces antibodies that instead of fighting infections, attacks body own tissues. Autoimmune diseases diagnosed with blood tests and review of disease history, symptoms and physical examination. Rheumatoid arthritis, type-1 diabetes, multiple sclerosis and lupus some of the major autoimmune diseases. Global autoimmune disease diagnostics market is expected to grow at significant rate owing to growing rates of autoimmune diseases. According to National Multiple Sclerosis Society (MS), approximately, 2.3 Mn people are living with multiple sclerosis worldwide. The market is composed of multinational and local companies involved in offering autoimmune diagnostics. Major players are involving in R&D for development and introduction of new diagnostics into the market. Market players are collaborating in order to develop the new diagnostics for the autoimmune diseases and further increasing the market portfolio. For instance, in November 2014, Protagen AG entered into a long-term collaboration with Qiagen to develop an innovative companion diagnostic development platform for autoimmune disorders. Furthermore, government and non-profit organizations are taking initiatives to increase the awareness and involving in development of diagnostics for autoimmune diseases. In November 2016, U.S. FDA has cleared Inova Diagnostic’s assay, “QUANTA LITE Calprotectin Extended Range” to help differentiate inflammatory bowel disease from irritating bowel disease. In November 2014, Adaptive Biotechnologies launched, immunoSEQ, research use only kit for diagnosing autoimmune.